Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H8O6 |
| Molecular Weight | 272.2097 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(O)C2=C1C(=O)C3=C(C2=O)C(O)=C(O)C=C3
InChI
InChIKey=VBHKTXLEJZIDJF-UHFFFAOYSA-N
InChI=1S/C14H8O6/c15-6-3-4-7(16)11-10(6)12(18)5-1-2-8(17)13(19)9(5)14(11)20/h1-4,15-17,19H
| Molecular Formula | C14H8O6 |
| Molecular Weight | 272.2097 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Quinalizarin, a specific enzyme protein kinase CK2 inhibitor, affects the cell proliferation, migration, and apoptosis of different pathological and genetic types of human lung cancer cell lines. This can be reached via ROS mediated MAPK and STAT3 signaling pathways. Also was revealed, that quinalizarin could induce apoptosis in gastric cancer cells via MAPK and Akt signaling pathway.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase. | 1991 Mar-Apr |
|
| Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus. | 1992 Jan |
|
| Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. | 1994 Sep-Oct |
|
| Hydroxyquinones are competitive non-peptide inhibitors of HIV-1 proteinase. | 1995 Nov 15 |
|
| Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. | 1996 Sep 3 |
|
| Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. | 1998 Sep |
|
| Quinalizarin anchored on Amberlite XAD-2. A new matrix for solid-phase extraction of metal ions for flame atomic absorption spectrometric determination. | 2001 Jun |
|
| Spectrophotometric determination of piroxicam and tenoxicam in pharmaceutical formulations using alizarin. | 2002 Jul 20 |
|
| Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. | 2004 Jan 9 |
|
| Spectrophotometric microdetermination of nefopam, mebevrine and phenylpropanolamine hydrochloride in pharmaceutical formulations using alizarins. | 2004 Jul |
|
| Rapid determination of aluminum by UV-vis diffuse reflectance spectroscopy with application of suitable adsorbents. | 2006 Dec 15 |
|
| Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. | 2009 Jul 15 |
|
| Preconcentration and separation of ultra-trace beryllium using quinalizarine-modified magnetic microparticles. | 2009 Jul 30 |
|
| Selective cloud point extraction and graphite furnace atomic absorption spectrometric determination of molybdenum (VI) ion in seawater samples. | 2009 Sep 30 |
|
| The role of protein kinase CK2 in the regulation of the insulin production of pancreatic islets. | 2010 Oct 15 |
Sample Use Guides
In Vitro Use Guide
Curator's Comment: Quinalizarin inhibited lung cancer A549, NCI H460 and NCI H23 cells proliferation and induced A549 cell cycle arrest at the G0/G1 phase. Quinalizarin induced apoptosis by upregulating the expression of B cell lymphoma 2 (Bcl 2) associated agonist of cell death, cleaved caspase 3 and cleaved poly (adenosine diphosphate ribose) polymerase, and downregulating the expression of Bcl 2.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:28:50 GMT 2023
by
admin
on
Sat Dec 16 04:28:50 GMT 2023
|
| Record UNII |
6D43C3LYSG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m9436
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
4896
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
201-366-6
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
6D43C3LYSG
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
5004
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
DB08660
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
37495
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
DTXSID4052558
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
144046
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
QUINALIZARIN
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY | |||
|
81-61-8
Created by
admin on Sat Dec 16 04:28:50 GMT 2023 , Edited by admin on Sat Dec 16 04:28:50 GMT 2023
|
PRIMARY |